EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)

Andrea Casadei-Gardini, Lorenzo Canova, Federica Tosi, Silvia Camera, Elisa Bocchero, Pietro Pozzoni, Martina Torchio, Salvatore Corallo, Daniela Costantino, Annamaria Stagno, Giulia Grizzi, Rita Gengarle und 16 weitere

Liver International · 2026-05 · 46 (5)

DOI: 10.1111/liv.70640 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 16.04.2026. Verfasst von Andrea Casadei-Gardini und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Dual immune checkpoint blockade with tremelimumab plus durvalumab (STRIDE) is an established first‐line therapy for unresectable hepatocellular carcinoma (uHCC); however, real‐world evidence on its safety, toxicity kinetics and liver function dynamics remains limited. We aimed to evaluate the tolerability and on‐treatment changes in hepatic function and effectiveness in a multicentre cohort of patients treated with STRIDE in routine practice.

Methods

We conducted a retrospective analysis of prospectively collected data from 115 consecutive patients with uHCC treated with STRIDE across 12 centres in Lombardy, Italy. Clinical, biochemical and radiological variables were recorded at baseline and throughout the therapy. Adverse events were graded per CTCAE v5.0, and Child–Pugh was used to assess hepatic functional evolution. The temporal toxicity patterns were evaluated using smoothed hazard functions. Progression‐free survival (PFS), overall survival (OS) and competing‐risk cumulative incidences of progression and death were examined.

Results

The median follow‐up was 8.9 months. More than 80% of the adverse events occurred within the first 2 months, and severe toxicities were infrequent. Child–Pugh deterioration from class A to B occurred in 7.8% of patients from baseline to day 28, increasing to 12.1% by day 56. PFS was 5.7 months; the median OS was not reached, with OS rates of 78.2% at 6 months and 53.3% at 18 months. Progression was the predominant early event, with a cumulative incidence of 49.2% at 6 months.

Conclusions

In routine clinical practice, STRIDE shows reproducible effectiveness and a manageable safety profile, with an early and stabilising incidence of adverse events. Dynamic assessment of liver function shows that hepatic function declines modestly but is still clinically meaningful in affected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedItalyProgression-Free SurvivalAntineoplastic Agents, Immunological

Substanzen

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonaldurvalumabtremelimumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
  • Division of Hepatology, San Giuseppe Hospital, IRCCS MultiMedica, Milan, Italy.
  • The Falck Division of Medical Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Hepatology Unit, Department of Medicine, Alessandro Manzoni Hospital, ASST Lecco, Lecco, Italy.

ORCID-Profile: Mara Persano, Margherita Rimini, Massimo Iavarone

Förderung

  • Ministero della Salute

Zitieren

APA

Casadei-Gardini, A., Canova, L., Tosi, F., Camera, S., Bocchero, E., Pozzoni, P., Torchio, M., Corallo, S., Costantino, D., Stagno, A., Grizzi, G., Gengarle, R., Tomasello, G., Ansarin, N., Bruccoleri, M., Bencardino, K., Persano, M., Pino, M., Riva, A., …, & Iavarone, M. (2026). Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group). Liver International, 46(5). https://doi.org/10.1111/liv.70640

Vancouver

Casadei-Gardini A, Canova L, Tosi F, Camera S, Bocchero E, Pozzoni P, et al. Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group). Liver International. 2026;46(5). doi:10.1111/liv.70640

BibTeX
@article{CasadeiGardini2026,
  author = {Casadei-Gardini, Andrea and Canova, Lorenzo and Tosi, Federica and Camera, Silvia and Bocchero, Elisa and Pozzoni, Pietro and Torchio, Martina and Corallo, Salvatore and Costantino, Daniela and Stagno, Annamaria and Grizzi, Giulia and Gengarle, Rita and Tomasello, Gianluca and Ansarin, Nasim and Bruccoleri, Mariangela and Bencardino, Katia and Persano, Mara and Pino, Martina and Riva, Alessia and Vavassori, Sara and Argiento, Lorenzo and Mazzarelli, Chiara and De Giorgio, Massimo and Caremoli, Elena Rota and Rimini, Margherita and Pressiani, Tiziana and Rimassa, Lorenza and Iavarone, Massimo},
  title = {Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {5},
  doi = {10.1111/liv.70640}
}
Kostenlos starten →